Login to Your Account

Shaky spear? Bard in play for CKD with new wisdom as phase II/III trial begins

By Randy Osborne
Staff Writer

Thursday, February 23, 2017

Reata Pharmaceuticals Inc.'s chief medical officer, Colin Meyer, told BioWorld Today that an earlier phase III trial in CKD was stopped because of "a very specific safety finding that we did not understand at the time."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription